Alvotech (ALVO) Ownership
ALVO ownership summary
as of October 17, 2026- Institutions
- 12.8% of shares outstanding
- Insiders
- 59.68% of shares outstanding
- Shares outstanding
- 356.8M
- Float
- 140.8M shares available to trade
- Short interest
- 3.95% 6.4M shares short
- Days to cover
- 5.44 short interest up 9.3% vs prior month
- Institutions 12.81%
- Insiders 59.68%
- Other investors 27.52%
ALVO top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard Total Intl Stock Index Inv | 0.47% | 1.7M | $8.4M | — | August 31, 2026 |
| 2 | Vanguard Emerging Mkts Stock Idx Inv | 0.45% | 1.6M | $8.1M | — | August 31, 2026 |
| 3 | iShares Biotechnology ETF | 0.38% | 1.4M | $6.8M | −10,272 (−0.8%) | September 30, 2026 |
| 4 | T. Rowe Price International Discovery | 0.31% | 1.1M | $5.6M | — | August 31, 2026 |
| 5 | Stefnir Icelandic Growth | 0.22% | 792K | $4.0M | −95,646 (−10.8%) | September 30, 2026 |
| 6 | L&G Frontier Markets Eq Z USD Acc | 0.18% | 655K | $3.3M | — | August 31, 2026 |
| 7 | Eaton Vance Glbl Macro Abs Ret Advtg I | 0.17% | 593K | $3.0M | — | July 31, 2026 |
| 8 | iShares Genomics Immnlgy & Hlthcr ETF | 0.08% | 301K | $1.5M | +8,300 (+2.8%) | September 30, 2026 |
| 9 | iShares Nasdaq US Biotech ETF USD Acc | 0.08% | 277K | $1.4M | +2,312 (+0.8%) | September 30, 2026 |
| 10 | Vanguard FTSE All-Wld ex-US ETF | 0.08% | 276K | $1.4M | +18,571 (+7.2%) | August 31, 2026 |
| 11 | Schwab Emerging Markets Equity ETF™ | 0.05% | 182K | $910,965 | — | September 30, 2026 |
| 12 | Eaton Vance Glbl Macr Absolute Return I | 0.04% | 160K | $797,515 | — | July 31, 2026 |
| 13 | Fidelity Nasdaq Composite ETF | 0.04% | 132K | $660,190 | — | September 30, 2026 |
| 14 | Vanguard Total World Stock ETF | 0.03% | 125K | $623,050 | — | August 31, 2026 |
| 15 | State Street® SPDR® S&P® EM Sm Cp ETF | 0.03% | 102K | $512,000 | — | September 30, 2026 |
| 16 | Fidelity Nasdaq Composite Index | 0.03% | 102K | $510,855 | −90,564 (−47.0%) | August 31, 2026 |
| 17 | Vanguard FTSE All-World UCITS ETF | 0.02% | 77K | $384,990 | — | August 31, 2026 |
| 18 | Parametric Emerging Markets I | 0.02% | 67K | $333,500 | — | July 31, 2026 |
| 19 | Eurizon Equity EmMkts New Frntrs Z Acc | 0.02% | 61K | $306,930 | +2,945 (+5.0%) | July 31, 2026 |
| 20 | ARISTEA Sicav New Frontiers Eq S USD Acc | 0.02% | 60K | $298,730 | +59,746 (0.0%) | June 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
ALVO shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns ALVO
Institutional investors own 12.8% of Alvotech's shares and insiders 59.68%. Short interest is 3.95% of the float, or 5.44 days of average trading volume. The share count rose 14.6% since 2019.
Related: ALVO analyst forecast, ALVO key metrics. See the ALVO stock overview for the latest quote and news.
ALVO ownership FAQ
What percentage of Alvotech is owned by institutions?
Institutions hold 12.8% of Alvotech's shares outstanding; insiders hold 59.68%.
Which funds own Alvotech?
The largest fund holders of Alvotech are Vanguard Total Intl Stock Index Inv (0.47%), Vanguard Emerging Mkts Stock Idx Inv (0.45%), iShares Biotechnology ETF (0.38%), T. Rowe Price International Discovery (0.31%), Stefnir Icelandic Growth (0.22%).
What is Alvotech's short interest?
6.4M shares of Alvotech were sold short, 3.95% of the float; at the average daily volume it would take 5.44 days to cover.
How many shares of Alvotech are outstanding?
Alvotech has 356.8M shares outstanding, of which 140.8M are in the public float.